Management of infective gastroenteritis in adults a consensus statement by an expert panel convened by the British Society for the Study of Infection

Journal of Infection

Volumn 33, Issue 3, 1996, Pages 143-152

  Farthing, M ^a   Feldman, R ^b   Finch, R ^c   Fox, R ^d   Leen, C ^e   Mandal, B ^f   Moss, P ^g   Nathwani, D ^h   Nye, F ^d   Percival, A ⁱ   Read, R ^g   Ritchie, L ^j   Todd, W T A ^k,m   Wood, M ^l  

^a ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

^b QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^c NOTTINGHAM CITY HOSPITAL   (United Kingdom)

^d UNIVERSITY HOSPITAL AINTREE   (United Kingdom)

^e CITY HOSPITAL   (United Kingdom)

^f NORTH MANCHESTER GENERAL HOSPITAL   (United Kingdom)

^g ROYAL HALLAMSHIRE HOSPITAL   (United Kingdom)

^h King's Cross Hospital   (United Kingdom)

ⁱ ROYAL LIVERPOOL UNIVERSITY HOSPITAL   (United Kingdom)

^j Monklands Bellshill Hospitals NHS T ^*  (United Kingdom)

^k NHS LANARKSHIRE   (United Kingdom)

^l BIRMINGHAM HEARTLANDS HOSPITAL   (United Kingdom)

^m MONKLANDS HOSPITAL   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIARRHEAL AGENT; BISMUTH SALICYLATE; CIPROFLOXACIN; COTRIMOXAZOLE; DIPHENOXYLATE; KAOLIN; LOPERAMIDE; METRONIDAZOLE; NALIDIXIC ACID; NORFLOXACIN; OPIATE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TETRACYCLINE; VANCOMYCIN;

FLUID THERAPY; GASTROENTERITIS; HUMAN; REVIEW;

EID: 16144366065     PISSN: 01634453     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0163-4453(96)92057-5     Document Type: Article

References (62)

1. Du Pont HL, Cooperstock M, Corrado ML, Fekety R. General guidelines for the evaluation of new anti-infective drugs for the treatment of gastrointenstinal infections. Clin Infect Dis 1992; 15(suppl. 1): S228-S235.
2. Thuluvath PJ, McKendrick MW. Salmonella and complications related to age - Sheffield experience. Quar J Med 1988; 67: 497-503.
3. Ho M-S, Glass RI, Monroe SS et al. Viral gastroenteritis aboard a cruise ship. Lancet 1989; ii: 961-964.
4. Molla AM, Rahaman M, Sarker SA, Molla A. J Paediatr 1981; 98: 835-838.
5. Lambie AT, Robson JS. Disorders of water and electrolyte metabolism. In: A companion to medical studies. Vol 3. Blackwell Scientific Publications ISBN 0632 058307.
6. Avery ME, Snyder JD, Oral therapy for acute diarrhoea. The underused simple solution. N Eng J Med 1990; 323: 891-894.
7. Bennett RG, Greenough WB III. Diarrhoea: A ubiquitous disease in older persons. Clinical Report on Aging (from the American Geriatrics Society) 1987; 1: 1-9.
8. Svanteson B, Thoren A, Castor B et al. Acute diarrhoea in adults: aetiology, clinical appearance and therapeutic aspects. Scan J Inf Dis 1988; 20: 303-314.
9. Du-Pont HL, Hornick RB. Adverse effect of Lomotil therapy in shigellosis. JAMA 1973; 225: 1525-1528.
10. Rabbani GH, Greenough WB III, Holmgren J, Kirkwood B. Controlled trial of chlorpromazine as antisecretory agent in patients with cholera hydrated intravenously. Br Med J 1982; 284: 1361-1384.
11. Du-Pont HL, Sullivan P, Pickering LK et al. Symptomatic treatment of diarhoea with bismuth subsalicylate among students attending a Mexican University. Gastroenterology 1977; 73: 715-718.
12. Nalin DR, Cash RA. Kaolin and cholera. J Pak Med Ass 1970; 20: 177-182.
13. Portnoy BL, Du-Pont HL, Pruitt D, Abdo JA, Rodriguez JT. Antidirrhoeal agents in the treatment of acute diarrhoea in children. JAMA 1976; 236: 844-846.
14. Guerrant R, Bobak D. Bacterial and protozoal gastroenteritis. New Eng J Med 1992; 1: 138-142.
15. Gorbach SL. Bacterial diarrhoea and its treatment. Lancet 1987; ii: 1378-1382.
16. Cleary TG. Cytotoxin producing E. Coli and the haemolytic uraemia syndrome. Paediatr Clin North Amer 1988; 485-501.
17. Nathwani D, Grimshaw J, Taylor RJ, Ritchie LD, Douglas JG, Smith CC. Factors influencing general practitioners' referral to hospital of adults with presumed infective diarrhoea. Br J Gen Prac 1994; 44: 171-174.
18. Pichler H, Diridl G, Wolf D. Ciprofloxacin in the treatment of acute bacterial diarrhoea: a double blind study. Eur J Clin Microblol 1986; 5: 241-243.
19. Pichler HET, Diridl G, Stickler K, Wolf D. Clinical efficacy of ciprofloxacin compared with placebo in bacterial diarrhoea. Am J Med 1987; 82(Suppl. 4A): 329-332.
20. Wistrom J, Jertborn M, Ekwall et al. Empiric treatment of acute diarrhoea disease with Norfloxacin. Ann Int Med 1992: 117: 202-208.
21. Goodman LJ, Trenholme GM, Kaplan RL. Empirical antimicrobial therapy of domestically acquired acute diarrhoea in urban adults. Arch Int Med 1990; 150: 541-546.
22. Adler-MoscaH, Luthy-Hottehstein J, Martinetti Lucchini G, Burnens A, Altwegg M. Development of resistance to quinolones in five patients with campylobacteriosis treated with norfloxacin or ciprofloxacin. Eur J Microbiol Infect Dis 1991; 10: 953.
23. Nathwani D, Wood MJ. Ciprofloxacin and Salmonella carriage. J Hosp Infect 1992; 22: 181-184.
24. McIntrye M, Lyons M. Resistance to ciprofloxacin in campylobacter spp. Lancet 1993; 341: 188.
25. Bowler I, Day D. Emerging quinolone resistance in campylobacters. Lancet 1992; 340: 245.
26. Endtz HP, Ruijs GJ, Van Klingeren B, Jansen WH, Van Der Reyden T, Mouton RP. Quinolone resistance in campylobacter isolated from man and poultry following the introduction of fluoroquinolones in Veterinary Medicine. J Antimicrob Chemother 1991; 27: 119-208.
27. Navarro F, Miro E, Fuentes I, Mirelis B. Campylobacter species: identification and resistance to quinolones. Clin Infect Dis 1993; 17: 815-816.
28. Howard AJ, Joseph TD, Bloodworth LLO, Frost JA, Chart H, Rowe B. The emergence of ciprofloxacin resistance in Salmonella typhimurium. J Antimicrob Chemother 1990; 26: 296-298.
29. Anonymous. Quinolones in acute non-travellers' diarrhoea. Editorial. Lancet 1990; ii: 282.
30. Gotuzzo E, Oberhelman RA, Maguina C et al. Comparison of single dose treatment with norfloxacin and standard 5 day treatment with trimethoprim-sulphamethoxazole for acute shigellosis in adults. Antimicrobial Agents Chemother 1989; 33: 1101-1104.
31. Salam I, Katelaris P, Leigh-Smith S, Farthing MJG. Randomised trial of single-dose ciprofloxacin for travellers' diarrhoea. Lancet 1994; 344: 1537-1539.
32. Hansson HB, Barkenius G, Cronberg S, Juhlin I. Controlled comparison of naladixic acid or lactulose with placebo in shigellosis. Scand J Infect Dis 1981: 13: 191-193.
33. Bennish ML, Salam KA, Haider R, Barza M. Therapy for shigellosis II. Randomised double-blind comparison of ciprofloxacin and ampicillin. J Infect Dis 1990; 162: 711-716.
34. Lolekha S, Patanachareon S, Thanangkul B, Vibulbandhitkit S. Norfloxacin versus co-trimoxazole in the treatment of acute bacterial diarrhoea: a placebo controlled study. Scand J Infect Dis 1988; 56(SuppL): 35-45.
35. Sanchez C, Garcia-Restoy E, Garae J et al. Ciprofloxacin and trimethoprim-sulfamethoxazole versus placebo in acute uncomplicated salmonella enteritis: A double blind trial. J Infect dis 1993; 168: 1304-1306.
36. Salazar-Lindo E, Sack B, Chea-Woo E et al. Early treatment with erythromycin of Campylobacter jejuni associated dysentery in children. J Pediatr 1986; 109: 355-360.
37. Bichile LS, Saraswat K, Popat UR et al. Acute Campylobacter jejuni enteritis in 385 hospitalised patients. J Assoc Physicians India 1992; 40: 164-166.
38. Williams D, Schorling J, Barrett LJ et al. Early treatment of Campylobacter jejuni enteritis. Antimicrob Agents Chemother 1989; 33: 248-250.
39. Anders BJ, Lauer BA, Paisley JW et al. Double-blind placebo controlled trial of erythromycin for treatment of Campylobacter enteritis. Lancet 1982; 1: 131-132.
40. Pai CH, Gillis F, Tuomanen E et al. Erythromycin in treatment of Campylobacter enteritis in children. Am J Dis Child 1983; 137: 286-290.
41. Mandal BK, Ellis ME, Dunbar EM, Whale K. Double blind placebo controlled trial of erythromycin in the treatment of clinical Campylobacter infection. J Antimicrob Chemother 1984; 13: 619-623.
42. Lindebaum J, Greenough WB III, Islam MR. Antibiotic therapy of cholera. Bull WHO 1967; 36: 871-873.
43. Kabart K. Uylangco C, Vasco J et al. Observations on cholera treated orally and intravenously with antibiotics: with particular reference to the number of vibrios excreted in the stools. Bull WHO 1967; 37: 751-762.
44. Wallace CK, Anderson PN, Brown TC et al. Optimal antibiotic therapy in cholera Bull WHO 1968: 39: 239-254.
45. Sack DA, Islam S, Rabbani H et al. Single dose doxycycline for cholera. Antimicrob Agents Chemother 1978; 14: 462-464.
46. Rahaman MM, Majid MA, Alalla AK et al. Effects of doxycycline in actively pursing cholera patients. A double blind clinical trial. Antimicrob Agents Chemother 1976; 10: 610.
47. Swerdlow DL, Ries AA. Cholera in the Americas: guidelines for the clinician. J Am Med Assn 1992; 267: 1495-1499.
48. Oberhelman RA, de al Cabada, Garibay EV et al. Efficacy of Trimethoprim-sulfamethaxazole in treatment of acute diarrhoea in Mexican paediatric population. J Pediat 1987; 110: 960-965.
49. Black RE, Levine MM, Clements ML et al. Treatment of experimentally induced enterotoxigenic Escherichia coli diarrhoea with trimethoprim, trimethoprim-sulfamethaxazole, or placebo. J Infect Dis 1982; 4: 430-437.
50. Ericsson CD, Johnson PC, Dupont HL et al. Ciprofloxacin or trimethoprim/sulfamethaxazole as initial therapy for travellers' diarrhoea. Ann Intern Med 1987; 106: 216-220.
51. Teasley DG, Gerling DN, Olson MM et al Prospective randomised trial of metronidazole versus vancomycin for Clostridium difficile associated diarrhoea and colitis. Lancet 1983: 2: 1043-1046.
52. Peterson LR, Gerdin DL. Antimicrobial agents in Clostridium difficileassociated intestinal diseases. In: Ramband JC, Ducluzeau R, eds. Clostridium difficile et pathologie. Paris: Springer-Verlag, 1990: 115-127.
53. Scott DA, Edelman R. Treatment of gastrointestinal infections. In: Bailliere's Clinical Gastroenterology 1993; 7: 477-499.
54. Nye FJ, Roberts C. Prolonged excretion of salmonellae. J Infect 1979; 1: 367-374.
55. Musher DN, Rushenstein AD. Permanent carriers of non typhosa salmonellae. Arch Intern Med 1973; 132: 869-872.
56. Reid TMS. The treatment of non-typhi salmonellosis. J Antimicrob Chemother 1992; 29: 4-8.
57. Damjanovic V, Williets TH, Glynne Thomas D, Van Saene HKF. Eradication of salmonella by oral ciprofloxacin in food handlers. Lancet 1990; 335: 974.
58. Lightfoot NF, Ahmad F, Cowden J. Management of institutional outbreaks of salmonella gastroenteritis. J Antimicrob Chemother 1990; 26(Suppl. F): 37-46.
59. Neil MA, Opal SM, Heelan J et al. Failure of ciprofloxacin to eradicate convalescent faecal excretion after salmonellosis: experience during an outbreak in health care workers. Ann Intern Med 1991; 114: 195-199.
60. Carl Stedt JP, Dahl P, Niklasson CH et al. Norfloxacin treatment of salmonellosis does not shorten carriers state. Scan J Infect Dis 1990; 22: 553-556.
61. Public Health Laboratory Services Salmonella Sub-Committee. The prevention of human transmission of gastrointestinal infections, infestations and bacterial intoxifications in the United Kingdom. Comm Dis Report 1995: Suppl. 11.
62. Consultants in Public Health Medicine (Communicable Diseases and Environmental Health) Working Group. Guidelines on bacteriological clearance following gastrointestinal infection. Comm Dis (Scotland) Weekly Report 1994; 28 (No. 94/26): 8-12.